Osteoartroz kolennogo sustava: sovremennye tendentsii medikamentoznogo lecheniya, rol' selektivnykh ingibitorov iklooksigenazy-2


Cite item

Full Text

Abstract

За последние несколько лет произошли значительные изменения в области медикаментозного лечения остеоартроза (ОА). Препараты с хондропротективными свойствами, появившиеся относительно недавно, уже стали неотъемлемой частью лечения этого заболевания. В то же время обезболивающие и противовоспалительные препараты, ранее являвшиеся основным методом лечения, не утратили своего значения.

About the authors

V. V Lyalina

Российский государственный медицинский университет, Москва

References

  1. Голубев Г.Ш., Кригштейн О.С. Оценка доказательств эффективности средств, претендующих называться структурно - модифицирующими препаратами. Междун. журн. мед. практики,2005,2:38-52.
  2. Мареев В.Ю. Кардиологический пациент и сопутствующая патология. Еще раз о кардиологической безопасности НПВП. Опубликовано www.OSSN.ru по материалам симпозиума Конгресса "Человек и Лекарство", 2005 г.
  3. Насонов Е.Л. Нестероидные противовоспалительные препараты (перспективы применения в медицине). М., "Анко", 2000.
  4. Насонов Е.Л., Чичасова Н.В., Ковалёв В.Ю. Глюкокортикоиды в ревматологии. М.,1998.
  5. Условия и требования к внутрисуставному и периартикулярному введению глюкокортикостероидных препаратов. Методические указания 2001/25 Министерства Здравоохранения РФ, М.,2001.
  6. Чичасова Н.В. Лечение остеоартроза. Влияние на хрящевую ткань различных противовоспалительных препаратов. Рус. Мед. журн. 2005;13 (8): 539-43.
  7. Arroll B, Goodyear-Smith F. "Corticosteroid injections for osteoarthritis of the knee: meta - analysis". BMJ, 2004, 328:869.
  8. Ayral X. Injections in the treatment of osteoarthritis. Best Pract Res Clin Rheumatol, 2001; 15: 609-26.
  9. Blot L, Marcelis A, Devogelaer J.P, Manicourt D.H. Effects of diclofenac, aceclofenac and meloxicam on the metabolism of proteoglycans and hyaluronan in osteoarthritic human cartilage. Br J Pharmacology, 2000, 131, 1413-21.
  10. Brandt K.D. The role of analgesics in the management of osteoarthritis pain. Am J Ther, 2000,7,75-90.
  11. Bruyere O, Compere S, Rovati L.C et al. Five - year follow up of patients from a previous 3-year randomized, controlled trial of Glucosamine sulfate in Knee Osteoarthritis. Arthr Rheum, 2003; 48(s):A89.
  12. Carrabba M, Paresce E et al. The safety and efficacy of different dose schedules of hyaluronic acid in the treatment of painful osteoarthritis of the knee with joint effusion. Eur J Rheumatol Inflamm, 1995, 15:25-31.
  13. Corrado E.M, Peluso G.F, Gigliotti S et al. The effects of intraarticular administration of hyaluronic acid on osteoarthritis of the knee: a clinical study with immunological and biochemical evaluations. Eur J Rheumatol Inflamm, 1995;15:47-56.
  14. Creamer P. Intraarticular corticosteroid treatment in osteoarthritis. Curr Opin Rheumatol., 1999, 11(5), 417-21.
  15. Dieppe P.A, Francel S.J, Toht B. Is research into the treatment of osteoarthritis with NSAIDs misdirected? Lancet, 1993, 341, 353-4.
  16. Dingle J.T. The effect of nonsteoridal anti - inflammatory drugs on human articular cartilage glycosaminoglycan synthesis. Osteoarthritis and cartilage, 1999,7, 313-14.
  17. Dougados M, Nguyen M, Listrat V, Amor B. High molecular weight sodium hyaluronate (hyalectin) in osteoarthritis of the knee: a 1 year placebo controlled trial. Osteoarthritis Cartilage, 1993, 1, 97-103.
  18. Gimbel J, Brugger A, Zhao W et al. Efficacy and tolerability of Celecoxib versus Hydrocodone/Acetaminophen in treatment of pain after ambulatory orthopedic surgery in adults. Clinic Therapeuti, 2201,V23,(#2), 228-41.
  19. Goldstein J.L, Eisen G.M, Lewis B. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol 2005;3,133-41.
  20. Graham D.J, Campen D.H, Hui R et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo - oxygenase 2 selective and non - selective non - steroidal anti - inflammatory drugs: nested case - control study. Lancet. 2005;365:475-81.
  21. Gray R, Tenenbaum J et al. Local corticosteroid injection treatment in rheumatic disorders. Sem Arthr Rheum, 1981; 10, 231-54.
  22. Huskisson E.C, Donelly S. Hyaluronic acid in the treatment of osteoarthritis of the knee. Rheumatology (Oxford), 1999; 38:602-7.
  23. Ike R.W. Therapeutic Injections of the joints and soft tissues, In: Primer on Rheumatic Diseases, 11th ed. Klippel J.H. The Arthritis Foundation. Atlanta.1997.
  24. Jansen T.L, Roon E.N Four cases of secondary Cushingoid state following local triamcinolone acetonide injection Neth J Med,2002,60:151-3.
  25. Johnson A.G, Nguyen T.V et al. Do nonsteroidal anti - inflammatory drugs affect blood pressure? A meta - analysis. Ann Intern Med, 1994,121,289-300.
  26. Jordan K.M, Arden N.K, Doherty M et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis,2003,62,1145-1155.
  27. Kauser H, Kley H. Cortisontherapie: Corticoid in Klinik und Praxis. Thieme, Stutgart, New York, 1997.
  28. Laporte J-R, Ibanez L et al. Upper gastrointestinal bleeding associated with the use of NSAIDs. Newer versus older agents. Drug Safety 2004; 27(6):411-420.
  29. Leeb B, Schweitzer H et al. A metaanalysis of chondroitin sulfate in the treatment of osteoarthritis. J Rheumatol, 2000, 27, 205-211.
  30. Listrat V, Ayral X et al. Arthroscopic evaluation of potential structure modifying activity of hyaluronan (Hyalgan) in osteoarthritis of the knee. Osteoarthritis cartilage, 1997, 5, 153-60.
  31. Lussier A, Cividino A.A et al. Viscosupplementation with Hylan for the treatment of osteoarthritis: findings from clinical practice in Canada. J Rheumatology, 1996, 23, 1579-85.
  32. Mamdami M, Juurlink D.N, Lee D.S et al. Cyclo - oxygenase-2 inhibitors vs non - selective nonsteroidal antiinflammatory drugs and congestive heart failure outcomes in elderly patients. A population - based cohort study. Lancet, 2004, 363,1751-6.
  33. Mastbergen S.C, Lafeber F.P et al. Selective COX-2 inhibition prevents proinflammatory cytokine - induced cartilage damage. Rheumatology 2002,41,801-808.
  34. Mazieres B, Combe B, et al. Chondroitin sulfate in osteoarthritis of the knee: a prospective double blind placebo - controlled multicenter clinical study. J Rheum, 2001, 28: 173-81.
  35. Mc Alindon T.E, La Valley M.P et al. Glucosamine and chondroitin for the treatment of osteoarthrosis. A systematic quality assessment and meta - analysis. JAMA, 2000,283, 1469-75.
  36. Pavelka K, Gatterova J, Olejarova M, et al. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo - controlled, double - blind study. Arch Intern Med, 2002; 162(18):2113-23.
  37. Pavelka K, Gatterova J, Giacovelli G et al. Glucosamine sulfate prevents total joint replacement in the long term follow up of knee osteoarthritis patients. Arthritis Rheum, 2004; 49(s): A251.
  38. Pope J.E, Anderson J.J et al. A meta - analysis of the effects of nonsteroidal anti - inflammatory drugs on blood pressure. Arch Intern Med,1993,153, 477-84.
  39. Raynauld J, Buckland-Wright C, Ward R, Choquette D et al. Safety and efficiency of long - term intraarticular steroid injections in osteoarthritis of the knee. Arthr Rheum, 2003 ;48, 370-7.
  40. Reginster J.Y, Deroisy R., Rovai L.C, et al. Long term effects of glucosamine sulfate on osteoarthritis progression: a randomized, placebo - controlled clinical trial. Lancet, 2001, 357 (9252): 251-6.
  41. Reid D, Eastmond C, Rennie J. Hypotalamo - pituitary - adrenal axis suppression after repeated intra - articular steroid injection. Ann Rheum Dis, 1986,45:45-87.
  42. Simon L.S, Lanza F.L et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacyand safety in two placebo - controlled tials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum. 1998 Sep;41(9):1591-602.
  43. Simon L.S, Weaver A.L, Graham D.Y et al. Anti - inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA. 1999;282:1921-8.
  44. Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. The Journal of Rheumatology, 1999, Volume 26, Supp. 56
  45. Singh G, Lanes S, Triadafilopoulos G. Risk of serious upper gastrointestinal and cardiovascular thromboembolic complications with Meloxicam. The American Journale of Medicine, 2004, 100-6.
  46. Singh G, Fort J.G, Goldstein J.L et al. for the SUCCESS-I Investigators. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I study. Am J Med. 2006;119:255-66.
  47. Todhunter R, Fubini S, Wooton J, Lust G. Effect of methylprednisolon acetate on proteoglycan and collagen metabolism of articular cartilage explants. J Rheumatol, 1996, 23,1207-13.
  48. Towheed T.E, Maxwell L, Anastassiades T.P, Shea B et al. Glucosamine therapy for treating osteoarthritis. The Cochrane Database reviews 2005, Issue 2.
  49. Tramer M.R, Moore R.A, Reynolds D.J.M, Mc Quay H.J. Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use. Pain. 2000;169-82.
  50. van Tuyl S.A.C, Slee P.H. Are the effects of local treatment with glucocorticoids only local? The Netherl. J. Med., 2202; 60, (3),130.
  51. Uelelhard D, Thonar E.J et al. Effect of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. Osteoarthritis cartilage, 1998, 6(suppl F): 49-56.
  52. Wobig M, Bach G, Beks P et al. The role of elastoviscosity in the efficacy of viscosupplementation for osteoarthritis of the knee: a comparison of hyalan G-F 20 and a lower molecular weight hyaluronan. Clin Ther, 1999; 21:1549-62.

Copyright (c) 2006 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies